The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 16, 2023

Filed:

Apr. 14, 2017
Applicants:

Immunext, Inc, Lebanon, NH (US);

Janssen Pharmaceuticals, Inc., Raritan, NJ (US);

Inventors:

Michael Molloy, Enfield, NH (US);

Jay Rothstein, Norwich, VT (US);

Dov Pechenick, New Hampton, NH (US);

Linda Snyder, Pottsdown, PA (US);

Gordon Powers, Malvern, PA (US);

Assignees:

IMMUNEXT, INC., Lebanon, NH (US);

JANSSEN PHARMACEUTICALS, INC., Raritan, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 17/06 (2006.01); A61P 1/16 (2006.01); A61P 37/06 (2006.01); A61P 19/02 (2006.01); A61P 13/12 (2006.01); A61P 1/00 (2006.01); A61K 45/06 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 38/17 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 1/16 (2018.01); A61P 13/12 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C07K 16/2827 (2013.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.


Find Patent Forward Citations

Loading…